| - IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite S | Amberg, Bad Saarow, Berlin | Phase II | rekrutiert |
| A Prospective Observational Trial to Assess Treatment Sequences and Factors That Impact Overall | Köln, Ulm | — | rekrutiert |
| A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination Wit | Berlin, Dortmund, Dresden | Phase III | rekrutiert |
| A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients W | Berlin, Bochum, Dresden | Phase I | rekrutiert |
| A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Re | Augsburg, Köln, Ulm | Phase I | rekrutiert |
| A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulce | Augsburg, Berlin, Brandenburg an der Havel | Phase II | rekrutiert |
| A Study of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis | Lübeck, Rostock, Ulm | Phase I | rekrutiert |
| A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Le | Dortmund, Dresden, Ulm | Phase III | rekrutiert |
| A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease | Aachen, Bad Homburg vor der Höhe, Bayreuth | Phase III | rekrutiert |
| A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy | Freiburg im Breisgau, Ulm, Köln | Phase II | rekrutiert |
| A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart ( | Berlin, Frankfurt am Main, Halle (Saale) | Phase III | rekrutiert |
| A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures | Aachen, Berlin, Bielefeld | Phase III | rekrutiert |
| A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and S | Dresden, Göttingen, München | Phase I | rekrutiert |
| A Trial to Compare Treatment With Surlorian (ARM210, S48168) to Placebo in Effects on Muscle Str | Ulm, Berlin | Phase II | rekrutiert |
| Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell | Homburg, Aschaffenburg, Berlin | Phase III | rekrutiert |
| Adjusted High-dose Chemotherapy With Autologous Stem Cell Transplant vs. Conventional Immunochem | Freiburg im Breisgau, Stuttgart, Aachen | Phase III | rekrutiert |
| Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination Wit | Dresden, Erlangen, Essen | Phase I / Phase II | rekrutiert |
| Cardiac Biomarkers for the Quantification of Myocardial Damage After Cardiac Surgery | Freiburg im Breisgau, Ulm, Münster | — | rekrutiert |
| Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Ad | Aachen, Augsburg, Bad Nauheim | Phase III | rekrutiert |
| Clinical Performance of the New Plasma Filter PX2 in TPE Treatments | Aschaffenburg, München, Braunschweig | ohne Phasenangabe | rekrutiert |
| Comparison of Therapies Before Stem Cell Transplantation in Patients With Higher Risk MDS and Ol | Aachen, Augsburg, Berlin | Phase II | rekrutiert |
| Fracture Monitor - Femur | Homburg, Münster, Tübingen | ohne Phasenangabe | rekrutiert |
| Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITIO | Heidelberg, Tübingen, Augsburg | Phase II | rekrutiert |
| German MPN-Registry for BCR-ABL 1-Negative Myeloid Neoplasms (Study Group Ulm) | Augsburg, Bad Saarow, Baden-Baden | — | rekrutiert |
| Improved Muscle Metabolism by Combination of Muscle Activation and Protein Substitution ( IMEMPR | München, Berlin, Ulm | ohne Phasenangabe | rekrutiert |
| Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phen | Augsburg, Berlin, Bonn | Phase III | rekrutiert |
| Intracoronary Stenting and Additional Results Achieved by ShockWAVE Coronary Lithotripsy | Heidelberg, Mannheim, Singen (Hohentwiel) | ohne Phasenangabe | rekrutiert |
| Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With | Berlin, Düsseldorf, Frankfurt am Main | Phase I / Phase II | rekrutiert |
| KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors | Berlin, Ulm, Würzburg | Phase I | rekrutiert |
| Long-term Follow-up of Children Born in the PETN Studies | Tübingen, Ulm, München | — | rekrutiert |
| NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-ne | Baden-Baden, Böblingen, Freiburg im Breisgau | Phase III | rekrutiert |
| NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HE | Baden-Baden, Freiburg im Breisgau, Tübingen | Phase II | rekrutiert |
| Neoadjuvant Darovasertib in Primary Uveal Melanoma | Tübingen, Ulm, Erlangen | Phase III | rekrutiert |
| Oral Pooled Fecal Microbiotherapy to Prevent Allogeneic Hematopoietic Cell Transplantation Compl | Augsburg, Berlin, Bonn | Phase II | rekrutiert |
| PACAREG: a Multicenter Registry Trial in Pancreatic Ductal Adencarcinoma | Ulm | — | rekrutiert |
| Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Mali | Ulm, München, Würzburg | Phase I | rekrutiert |
| Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib | Köln, Essen, Mönchengladbach | Phase III | rekrutiert |
| Post-Market Clinical Follow Up Study With Navitor Valve | Bad Bevensen, Berlin, Köln | — | rekrutiert |
| Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - POR | Amberg, Bad Saarow, Bayreuth | Phase III | rekrutiert |
| Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blin | Aachen, Aschaffenburg, Augsburg | Phase II | rekrutiert |
| Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study | Berlin, Bochum, Köln | — | rekrutiert |
| Safe and Timely Antithrombotic Removal (STAR) Registry | Coswig, Erlangen, Essen | — | rekrutiert |
| Safety and Efficacy of Intravenous Thrombolysis in Patients With Ischemic Stroke and Direct Oral | Karlsbad, Bad Neustadt an der Saale, Bamberg | Phase IV | rekrutiert |
| Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or | Ulm, Erlangen, München | Phase I / Phase II | rekrutiert |
| Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination | München, Frankfurt am Main, Kassel | Phase III | rekrutiert |
| Transcatheter Mitral Valve Replacement in Patients With Severe Symptomatic Mitral Regurgitation | Bad Oeynhausen, Berlin, Bonn | ohne Phasenangabe | rekrutiert |
| Transfemoral TAVI With or Without Coronary Angiogram in Patients With Severe Aortic Stenosis (PU | Düsseldorf, Essen, Freiburg im Breisgau | ohne Phasenangabe | rekrutiert |
| Treatment Guided by Comprehensive Genome and Transcriptome Analysis Versus Standard of Care in A | Augsburg, Berlin, Köln | — | rekrutiert |
| Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metast | Berlin, Bielefeld, Dresden | Phase II | rekrutiert |